Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 8/20 | 0.46 |
| ▸ | AURKB | Q96GD4 | 7/20 | 0.46 |
| ▸ | RIPK1 | Q13546 | 5/20 | 0.46 |
| ▸ | PLK4 | O00444 | 3/20 | 0.46 |
| ▸ | AURKC | Q9UQB9 | 3/20 | 0.46 |
| ▸ | SRC | P12931 | 2/20 | 0.46 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.46 |
| ▸ | STK25 | O00506 | 1/20 | 0.46 |
| ▸ | RIOK3 | O14730 | 1/20 | 0.46 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.46 |
| ▸ | GAK | O14976 | 1/20 | 0.46 |
| ▸ | MUSK | O15146 | 1/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | MAP3K13 | O43283 | 1/20 | 0.46 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.46 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.46 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3673996 | 1.00 | AURKA (0.46) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL12341505 | 0.86 | AURKA (0.44) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL3644101 | 0.82 | AURKA (0.41) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL3644098 | 0.82 | AURKA (0.41) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL375438 | 0.81 | AURKB (0.47) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL12694190 | 0.77 | AURKA (0.66) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL13299441 | 0.77 | AURKB (0.62) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL12338737 | 0.76 | AURKA (0.67) | AURKAAURKBRIPK1PLK4AURKC | |
| SCHEMBL648099 | 0.76 | AURKA (0.58) | AURKAAURKBRIPK1PLK4AURKC | |
| Tozasertib SCHEMBL614528 | 0.76 | AURKB (0.78) | AURKAAURKBRIPK1PLK4AURKC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110060013-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | claimed |
| EP-2164842-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | claimed |
| WO-2008147626-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-04 | — | — | WO | claimed |
| US-20110060013-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| EP-2164842-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | Vertex Pharmaceuticals Incorporated (US) | 2010-03-24 | — | — | EP | disclosed |
| WO-2008147626-A2 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110060013-A1 | THIAZOLES AND PYRAZOLES USEFUL AS KINASE INHIBITORS | AURKC, AURKA, AURKB | AURKA 2/4885AURKB 3/4885RIPK1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.